IP Verse

Agent For Locally Treating Cervical Dysplasias - EP2558116

The patent EP2558116 was granted to Charit Universittsmedizin Berlin on Jan 8, 2020. The application was originally filed on Apr 15, 2011 under application number EP11727394A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2558116

CHARIT UNIVERSITTSMEDIZIN BERLIN
Application Number
EP11727394A
Filing Date
Apr 15, 2011
Status
Patent Maintained As Amended
Dec 6, 2019
Grant Date
Jan 8, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GLAXOSMITHKLINEDec 21, 2017RACINEADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONDE102004039875
DESCRIPTIONUS2006171949
DESCRIPTIONUS2007098719
DESCRIPTIONWO2009106362
INTERNATIONAL-SEARCH-REPORTWO2008138648
INTERNATIONAL-SEARCH-REPORTWO2009106362
OPPOSITIONUS6706728
OPPOSITIONUS7659071
OPPOSITIONWO2004060408
OPPOSITIONWO2007121893
OPPOSITIONWO2008106646
OPPOSITIONWO2009106362

Non-Patent Literature (NPL) Citations (34) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- APPLEDORN, DANIEL M. et al., "Sublingual administration of an adenovirus serotype 5 (Ad5)- based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell -mediated responses against HIV antigens despite preexisting Ad5 immunity", Clinical and Vaccine Immunology, (20110100), vol. 18, no. 1, pages 150 - 160-
OPPOSITION- BABIUK, L. A. et al., "Adenoviruses as vectors for delivering vaccines to mucosal surfaces", Journal of biotechnology, (20000000), vol. 83, no. 1, pages 105 - 113-
OPPOSITION- BALAGUÉ, CRISTINA et al., "Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes", Journal of virology, (20010000), vol. 75, no. 16, pages 7602 - 7611-
OPPOSITION- CROYLE, MARIA A. et al., "Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice", PloS one, (20080000), vol. 3, no. 10, page E3548-
OPPOSITION- Cuburu N. et al, "Adenovirus vector-based prime-boost vaccination via heterologous routes induses cervicovaginal CD8+ T cell responses against HPV16 oncoproteins", International Journal of Cancer, (20170000), pages 1 - 13-
OPPOSITION- DE SOUZA, APD. et al., "Genital CD 8+T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus", Vaccine, (20070000), vol. 25, no. 1, pages 109 - 116-
OPPOSITION- DE SOUZA, APD. et al., "Genital CD 8+T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus", Vaccine, (20070000), vol. 25, no. 1, pages 109 - 116, XP005797690-
OPPOSITION- DIAZ-ARRASTIA , CONCEPCION et al., "Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%", Clinical cancer research, (20010000), vol. 7, no. 10, pages 3031 - 3033-
OPPOSITION- DIAZ-ARRASTIA , CONCEPCION et al., "Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%", Clinical cancer research, (20010000), vol. 7, no. 10, pages 3031 - 3033, XP055453527-
OPPOSITION- DOORBAR J et al., "The Biology and Life-Cycle of Human Papillomaviruses", Vaccine, (20120000), pages F55 - F70-
OPPOSITION- DOORBAR J, "The papillomavirus life cycle", Journal of Clinical Virology, (20050000), vol. 32S, pages S7 - S15-
OPPOSITION- GAMBOTTO, ANDREA et al., "Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12", Cancer gene therapy, (19990000), vol. 6, no. 1, pages 45 - 53-
OPPOSITION- HEIDEMAN, DANIELLE AM et al., "Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer", Molecular Therapy, (20050000), vol. 12, no. 6, pages 1083 - 1090-
OPPOSITION- HOFFMANN, CORINNA et al., "Combining T- cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice", Journal of Immunotherapy, (20100200), vol. 33, no. 2, pages 136 - 145-
OPPOSITION- LANZA, SILVIA R. et al., "Simian recombinant adenovirus delivered by the mucosal route modulates gammadelta T cells from murine genital tract", Vaccine, (20100500), vol. 28, no. 29, pages 4600 - 4608-
OPPOSITION- MEYSKENS, FRANK L. et al., "Prevention of cervical intraepithelial neoplasia and cervical cancer", The American journal of clinical nutrition, (19950000), vol. 62, no. 6, pages 1417S - 1419S-
OPPOSITION- MEYSKENS, FRANK L. et al., "Prevention of cervical intraepithelial neoplasia and cervical cancer", The American journal of clinical nutrition, (19950000), vol. 62, no. 6, pages 1417S - 1419S, XP055453535-
OPPOSITION- "NCI Dictionary of Cancer terms", NIH, page 1-
OPPOSITION- RUDIN, CHARLES M. et al., "An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia", Journal of clinical oncology, (20030000), vol. 21, no. 24, pages 4546 - 4552-
OPPOSITION- Schiffman M.; Wentzensen N., "Human Papillomavirus (HPV) infection and the multi-stage carcinogenesis of cervical cancer", Cancer Epidemiol Biomarkers Prev., (20130000), vol. 22, no. 4, pages 553 - 560-
OPPOSITION- "the cervix", Canadian Cancer Society, URL: http://www.cancer.ca/en/cancer-information/cancer-type/cervical/cervical-cancer/the-cervix/?region=on-
OPPOSITION- Zervixzytology (Auf dem Laufenden, 2016), (https://twitter.com/eurocytology)-
OPPOSITION- STEINWAERDER et al., "Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes", Molecular Therapy, (20010000), vol. 4, no. 3, pages 211 - 216, XP001061267
OPPOSITION- DOORBAR J, "The papillomavirus life cycle", Journal of Clinical Virology, (20050000), vol. 32S, pages S7 - S15, XP055543437
OPPOSITION- LANZA, SILVIA R. et al., "Simian recombinant adenovirus delivered by the mucosal route modulates gammadelta T cells from murine genital tract", Vaccine, (20100500), vol. 28, no. 29, pages 4600 - 4608, XP027474774
OPPOSITION- DOORBAR J et al., "The Biology and Life-Cycle of Human Papillomaviruses", Vaccine, (20120000), pages F55 - F70, XP055543439
OPPOSITION- HEIDEMAN, DANIELLE AM et al., "Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer", Molecular Therapy, (20050000), vol. 12, no. 6, pages 1083 - 1090, XP005166230
OPPOSITION- BABIUK, L. A. et al., "Adenoviruses as vectors for delivering vaccines to mucosal surfaces", Journal of biotechnology, (20000000), vol. 83, no. 1, pages 105 - 113, XP004212158
OPPOSITION- GAMBOTTO, ANDREA et al., "Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12", Cancer gene therapy, (19990000), vol. 6, no. 1, pages 45 - 53, XP055292160
OPPOSITION- HOFFMANN, CORINNA et al., "Combining T- cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice", Journal of Immunotherapy, (20100200), vol. 33, no. 2, pages 136 - 145, XP008143422
OPPOSITION- APPLEDORN, DANIEL M. et al., "Sublingual administration of an adenovirus serotype 5 (Ad5)- based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell -mediated responses against HIV antigens despite preexisting Ad5 immunity", Clinical and Vaccine Immunology, (20110100), vol. 18, no. 1, pages 150 - 160, XP055453515
OPPOSITION- BALAGUE, CRISTINA et al., "Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes", Journal of virology, (20010000), vol. 75, no. 16, pages 7602 - 7611, XP002215977
OPPOSITION- RUDIN, CHARLES M. et al., "An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia", Journal of clinical oncology, (20030000), vol. 21, no. 24, pages 4546 - 4552, XP002982638
OPPOSITION- CROYLE, MARIA A. et al., "Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice", PloS one, (20080000), vol. 3, no. 10, page e3548, XP055381714

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents